<DOC>
	<DOCNO>NCT02910492</DOCNO>
	<brief_summary>Single-center study evaluate safety efficacy investigational version enlighten™ 670nm laser photo-rejuvenation .</brief_summary>
	<brief_title>Study Novel Laser Skin Rejuvenation</brief_title>
	<detailed_description>A single-center prospective , open-label uncontrolled exploratory study evaluate safety efficacy investigational version enlighten™ 670nm laser photo-rejuvenation . Subjects receive 7 laser treatment , space 1 8 week apart , follow 2 week ( ±1 week ) post-first treatment 12 week ( ±2 week ) post-final treatment . In addition , treatment , subject complete 3 day post treatment phone follow-up . At Investigator 's discretion , optional follow-up visit may also conduct 6 week post-final treatment ( ±2 week ) .</detailed_description>
	<criteria>Female Male , 20 75 year age ( inclusive ) . Fitzpatrick Skin Type I VI . Desires photorejuvenation skin improvement appearance acne scar . Subject visible sign acne scar moderate sundamaged and/or age skin treatment area visible area acne lesion scar , fine rhytides , lentigo pigmentation , diffuse redness erythema skin texture Subject must able read , understand sign Informed Consent Form . Must willing able adhere treatment followup schedule posttreatment care instruction . Willing limited sun exposure use approve sunscreen SPF 50 high treatment area every day duration study , include followup period . Willing digital photograph take treatment area agree use photograph presentation , educational marketing purpose . Agree undergo procedure ( ) , include injectable agent , skin rejuvenation study intention procedure perform course study . Postmenopausal surgically sterilize , use medically acceptable form birth control least 3 month prior enrollment entire course study , plan become pregnant . Participation clinical trial another drug , device administer target area , study . Any type prior cosmetic treatment target area within 6 month study participation , laser lightbased procedure surgery . Prior injection botulinum toxin , collagen , hyaluronic acid filler dermal filler within 6 month study participation . History malignant tumor target area . Skin abnormalities target area , e.g. , cut , scrape , wound , large mole . Pregnant and/or breastfeeding . Having infection , dermatitis rash treatment area . Significant concurrent illness , diabetes mellitus cardiovascular disease , e.g. , uncontrolled hypertension . History keloid scarring , hypertrophic scar abnormal wound healing . History immunosuppression/immune deficiency disorder currently use immunosuppressive medication per investigator 's discretion . History vitiligo , eczema , psoriasis . History connective tissue disease , systemic lupus erythematosus scleroderma . History seizure disorder due light . Any use medication know increase sensitivity light accord Investigator 's discretion . History disease stimulate heat , recurrent herpes simplex and/or herpes zoster ( shingle ) treatment area , unless treatment conduct follow prophylactic regimen History pigmentary disorder , particularly tendency hyper hypopigmentation . Systemic use retinoid , isotretinoin , applicable , within 6 month study participation . Topical use retinoid , isotretinoin , applicable , treatment area within 1 month participation . Anytime life , use gold therapy ( gold salt ) disorder rheumatologic disease lupus . Excessively tanned area treat unable/unlikely refrain tan study . Current smoker history smoking within 6 month study participation . As per Investigator 's discretion , physical mental condition might make unsafe subject participate study .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>